Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revive Therapeutics Ltd (OP:RVVTF)

0.0094 -0.0002 (-2.08%)
Streaming Delayed Price Updated: 3:56 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Revive Therapeutics Ltd

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Psychedelics Company Revive Raises $3.2M To Target Infectious Diseases, Disorders
Life sciences company Revive Therapeutics Ltd. (OTCQB: RVVTF) raised funds to treat infectious diseases and rare disorders, including meth addiction.< 
Via Benzinga
Revive Therapeutics Ltd. Closes $4.3 Million Offering
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Publication Showing Bucillamine’s Potential Impact on COVID-19 Omicron Variants
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. 
Via Benzinga
Psyence, Revive Therapeutics Ink Private Placements: Capital To Support Drug Trials
Life sciences biotech Psyence Group Inc. (OTCQB: PSYGF) has closed the second tranche of its previously announced private placement of up to $2.2 million (CA$3 million). 
Via Benzinga
Revive Therapeutics Ltd. Expands Life Offering to Quebec
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics To Raise Up To $5M Via Private Placement
REVIVE THERAPEUTICS LTD. (OTCQB: RVVTF) (CSE:RVV) announced that it is arranging a private placement of a minimum of $3 million and up to $5 million of units, at a price of $0.15 per unit;. 
Via Benzinga
Revive Therapeutics Ltd. Announces Offering of Up to $5 Million
From Revive Therapeutics Ltd.
Via GlobeNewswire
Psychedelic Stock Gainers And Losers From November 30, 2022
 
Via Benzinga
Revive Therapeutics, Seelos Therapeutics Among Top Psychedelic Movers Of Today
 
Via Benzinga
Revive Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 25, 2022
 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 24, 2022
 
Via Benzinga
Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Psychedelic Stock Gainers And Losers From November 23, 2022
 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 22, 2022
 
Via Benzinga
Revive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Psychedelic Stock Gainers And Losers From November 21, 2022
 
Via Benzinga
Biomind Labs, ATAI Life Sciences Among Top Psychedelic Movers Of Today
 
Via Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today
 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 16, 2022
 
Via Benzinga
GH Research, Seelos Therapeutics Among Top Psychedelic Movers Of Today
 
Via Benzinga
Compass Pathways, Mind Medicine Among Top Psychedelic Movers Of Today
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 12.17% at $10.05 
Via Benzinga
Seelos Therapeutics, GH Research Among Top Psychedelic Movers Of Today
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 7.91% at $9.96 LOSERS: 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 8, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 3.85% at $0.14 
Via Benzinga
Compass Pathways, Allied Among Top Psychedelic Movers Of Today
GAINERS: Allied (OTC:ALID) shares closed up 4.10% at $0.44 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 3, 2022
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 4.80% at $10.27 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.